Keith Usiskin

8.0k total citations · 5 hit papers
40 papers, 4.3k citations indexed

About

Keith Usiskin is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Keith Usiskin has authored 40 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Surgery and 15 papers in Genetics. Recurrent topics in Keith Usiskin's work include Diabetes Treatment and Management (22 papers), Inflammatory Bowel Disease (15 papers) and Pancreatic function and diabetes (12 papers). Keith Usiskin is often cited by papers focused on Diabetes Treatment and Management (22 papers), Inflammatory Bowel Disease (15 papers) and Pancreatic function and diabetes (12 papers). Keith Usiskin collaborates with scholars based in United States, Canada and Belgium. Keith Usiskin's co-authors include Gary Meininger, Albert Fung, Kaj Stenlöf, William Canovatchel, Daniel J. Sullivan, George Capuano, David Polidori, John P. Bilezikian, Nelson B. Watts and Bruce W. Bode and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Keith Usiskin

39 papers receiving 4.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

2012 513 citations Kaj Stenlöf, William T. Cefalu et al. Diabetes Obesity and Metabolism profile →
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

2013 418 citations J.‐F. Yale, George L. Bakris et al. Diabetes Obesity and Metabolism profile →
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

2012 364 citations David Polidori, Yue Zhao et al. profile →
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

2015 337 citations Nelson B. Watts, John P. Bilezikian et al. The Journal of Clinical Endocrinology & Metabolism profile →
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →

Peers

Countries citing papers authored by Keith Usiskin

Since Specialization

Citations

This map shows the geographic impact of Keith Usiskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Usiskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Usiskin more than expected).

Fields of papers citing papers by Keith Usiskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Usiskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Usiskin. The network helps show where Keith Usiskin may publish in the future.

Co-authorship network of co-authors of Keith Usiskin

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Usiskin. A scholar is included among the top collaborators of Keith Usiskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Usiskin. Keith Usiskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study 2021 ·Journal of Crohn s and Colitis ·William J. Sandborn, Brian G. Feagan, Stephen B. Hanauer, Séverine Vermeire, Subrata Ghosh, (unknown), AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert D’Haens	82
2	活動性潰瘍性大腸炎患者の無作為化試験におけるホスホジエステラーゼ4の経口阻害剤,アプレミラストの効果【JST・京大機械翻訳】 2020 ·Clinical Gastroenterology and Hepatology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Amanda S. Corey, Remo Panaccione, (unknown), Keith Usiskin, (unknown)	4
3	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis 2020 ·Clinical Gastroenterology and Hepatology ·Silvio Danese, Markus F. Neurath, (unknown), Salam Zakko, Timothy Simmons, Ronald Fogel, Corey A. Siegel, Remo Panaccione, Xiaojiang Zhan, Keith Usiskin, Denesh K. Chitkara	65
4	P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study 2020 ·The American Journal of Gastroenterology ·(unknown), (unknown), (unknown), (unknown), Igor Jovanović, Subrata Ghosh, (unknown), (unknown), (unknown), Lorna Charles, Keith Usiskin, Silvio Danese, (unknown)	14
5	813 - Apremilast for Active Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study 2018 ·Gastroenterology ·Silvio Danese, Markus F. Neurath, (unknown), Salam Zakko, Timothy Simmons, Ronald Fogel, (unknown), Xiaojiang Zhan, Keith Usiskin, Denesh K. Chitkara	4
6	PD-008 A Study of Oral Mongersen (GED-0301) on Endoscopy and Clinical Activity (Stool Frequency and Abdominal Pain) in Crohn's Disease 2017 ·Inflammatory Bowel Diseases ·(unknown), (unknown), Guillermo Rossiter, (unknown), Keith Usiskin, (unknown), (unknown)	1
7	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease 2017 ·Gastroenterology ·Brian G. Feagan, Bruce E. Sands, Guillermo Rossiter, Bin Li, Keith Usiskin, (unknown), Jean‐Frédéric Colombel	54
8	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin 2015 ·The Journal of Clinical Endocrinology & Metabolism ·John P. Bilezikian, Nelson B. Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel J. Sullivan, Norm Rosenthal	216
9	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes 2015 ·Diabetologia ·William T. Cefalu, Kaj Stenlöf, Lawrence A. Leiter, John Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel J. Sullivan, Keith Usiskin, William Canovatchel, Gary Meininger	111
10	Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results 2014 ·Postgraduate Medicine ·Keith Usiskin, Irina Kline, Albert Fung, Cristiana Mayer, Gary Meininger	82
11	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy 2014 ·American Journal of Nephrology ·Hala Yamout, Vlado Perkovic, Melanie J. Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger, George L. Bakris	91
12	Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies 2014 ·BMC Endocrine Disorders ·Alan J. Sinclair, Bruce W. Bode, Stewart B. Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai, Gary Meininger	73
13	Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor 2014 ·Postgraduate Medicine ·Lindsay E. Nicolle, George Capuano, Albert Fung, Keith Usiskin	73
14	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) 2014 ·Current Medical Research and Opinion ·Matthew R. Weir, Irina Kline, John Xie, Robert Edwards, Keith Usiskin	96
15	Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants 2014 ·Clinical Pharmacology in Drug Development ·Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Donna Skee, Ewa Wajs, Rao N. V. S. Mamidi, Hong Tian, An Vandebosch, Shean‐Sheng Wang, Tom Verhaeghe, Hans Stieltjes, Keith Usiskin	18
16	Long-Term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks 2014 ·Canadian Journal of Diabetes ·Stewart B. Harris, Bruce W. Bode, Kaj Stenlöf, Daniel J. Sullivan, Albert Fung, Keith Usiskin	2
17	Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial 2013 ·Hospital Practice ·Bruce W. Bode, Kaj Stenlöf, Daniel J. Sullivan, Albert Fung, Keith Usiskin	211
18	Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease breakdown → 2013 ·Diabetes Obesity and Metabolism ·J.‐F. Yale, George L. Bakris, Bertrand Cariou, Dennis K. Yue, Elias David‐Neto, Liwen Xi, (unknown), Ewa Wajs, Keith Usiskin, Gary Meininger	418
19	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial 2013 ·International Journal of Clinical Practice ·John Wilding, G. Charpentier, Priscilla Hollander, Guillermo González-Gálvez, Chantal Mathieu, Frank Vercruysse, Keith Usiskin, Ga‐Lai Law, Simon Black, William Canovatchel, Gary Meininger	276
20	Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor 2012 ·Current Medical Research and Opinion ·Paul Nyirjesy, Yue Zhao, Kirk Ways, Keith Usiskin	119

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact